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Abstract  
Damage of non-vascularised tissues such as cartilage and cornea can result in healing 
processes accompanied by a non-physiological angiogenesis. Peptidic aptamers have recently 
been reported to block the vascular endothelial growth factor (VEGF). However, the 
therapeutic applications of these aptamers is limited due to their short half-life in vivo. In this 
work, an enhanced stability and bioavailability of a known VEGF blocker aptamer sequence 
(WHLPFKC) was pursued through its tethering of molecular scaffolds based on 
hyperbranched peptides, the poly(ɛ-lysine) dendrons, bearing three branching generations. 
The proposed design allowed simultaneous and orderly-spaced exposure of sixteen aptamers 
per dendrimer to the surrounding biological microenvironent, as well as a relatively 
hydrophobic core based on di-phenylalanine aiming to promote an hydrophobic interaction 
with the hydrophobic moieties of ionically-crosslinked metacrylated gellan gum (iGG-MA) 
hydrogels. The VEGF blocker dendrons were entrapped in iGG-MA hydrogels and their 
capacity to prevent endothelial cell sprouting was assessed qualitatively and quantitatively 
using 3D in vitro models and the in vivo chick chorioallantoic membrane (CAM) assay. The 
data demonstrate that at nanoscale concentrations, the dendronised structures were able to 
enhance control of the biological actvity of WHLPFKC at the material/tissue interface and 
hence the anti-angiogenic capacity of iGG-MA hydrogels not only preventing blood vessel 
invasion, but also inducing their regression at the tissue/iGG-MA interface. The in ovo study 
confirmed that iGG-MA functionalised with the dendron VEGF blockers do inhibit 
angiogenesis by controlling both size and ramifications of blood vessels in proximity of the 
implanted gel surface. 
Keywords 
Tissue regeneration, angiogenesis, anti-angiogenesis peptide, dendron, gellan gum, vascular 
endothelial growth factor. 
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1. Introduction 
The invasion of healthy joint and intervertebral disc cartilage by fibrous tissue in pathological 
conditions such as osteoarthritis and rheumatoid arthritis as well as in traumatic and 
degenerative conditions is a consquence of abnormal angiogenesis (Pulsatelli et al., 2013). 
Pathological angiogenesis is linked by biochemical signalling to the insurgence of the 
inflammation causing the progressive degeneration of cartilage (Bonnet and Walsh, 2005). In 
clinics, non-steroidal anti-inflammatories drugs are administred to control inflammation and 
minimise joint damage, but these treatments neither improve the overall quality of life of the 
patient nor favour the repair of the degenerated tissue. The pathogenesis of other 
inflammatory disorders including synovial joints (Troken et al., 2007) and macular 
degeneration (AMD) (Xu et al., 2013) have also been associated to pathological 
angiogenesis, but appropriate therapies have not yet been identified (Carmeliet, 2003). 
However, it is widely accepted that drugs such as Sorafenib (Nexavar, Bayer) and 
Bevacizumab (AvastinTM, Genentech), acting directly on the prime driver in the process of 
blood vessel sprouting, i.e. the vascular endothelial growth factor (VEGF), have been 
sucessfully used to control angiogenesis (Bischoff and Griffioen, 2008). Indeed, clinical 
therapies commonly target VEGF either to decrease its levels or to block its activation and 
any subsequent downstream signaling pathway (Kim et al., 2011).  It has also been 
ascertained that the therapeutic efficacy of the various VEGF blockers available can be 
improved only by ensuring: (i) directed targeting of the effect of the blocker on endothelial 
cells (ECs) and (ii) the increased in situ retention of the blocker protracting the effect in the 
degenerated tissue (Wang, 2003).  
To this end, the search for new anti-angiogenic agents of enhanced therapeutic efficacy has 
more recently been directed towards aptamers. Aptamers are oligonucleotides such as 
ribonucleic acid (RNA) and single-strand deoxyribonucleic acid (ssDNA) who have shown 
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high binding affinitiy towards a wide range of extra- and intracellular molecular targets (e.g. 
proteins, peptides or even cells) (Tuerk and Gold, 1990). Among them, synthetic peptidic 
aptamers have shown greater  value in the treatment of vascular disorders (e.g. WHLPFKC 
sequence) (Erdag et al., 2007), but  their clinical use is restricted by their relatively short half-
life in vivo  (Nugent and Edelman, 2003) In the pursuit of enhancing their retention time in 
target tissues and anti-angiogenic effects,  dendrons ensuring a multiple and spacially-ordered 
presentation of of the anti-angiogenic linear VEGF blocker peptide WHLPFKC have 
previously been investigated (Meikle et al., 2011). The rationale in the design of such a type 
of poly-(ɛ-lysine) [K] dendron of third generation [Gen3] was to expose simultaneously to the 
biological microenvironment a high number (16 per dendrons) of WHLPFKC and to increase 
the stability and interactions of this new anti-VEGF aptamer within the tissue extracellular 
matrix and/or at the surface of a biomaterial through the integration at the molecular root of a 
di-phenilalanine root [FF]. These VEGF blocker dendrons, named as 
FFGen3K(WHLPFKC)16 have provided evidence of anti-proliferative and apoptotic effects 
on human umbelical vascular endothelial cells (HUVEC) as well as inhibitory effect on their 
sprouting  in in vitro models (Meikle et al., 2011).  
These findings appear to offer future therapeutic opportunities when combined with the 
recent discovery of the properties of a novel hydrogels, the ionic-crosslinked methacrylated 
gellan gum (iGG-MA) hydrogels that was firstly described by Silva-Correia et al. (2011; 
2012a-b; 2013a-b). The effects of combining the iGG-MA hydrogel discs with 
FFGen3K(WHLPFKC)16 has recently been studied in an ovine nucleotomy model showing a 
significant improvement in the regeneration of tissues with physicological features (Reitmaier 
et al., 2014).   
The present study aims to demonstrate the high level of control over angiogenesis offered by 
iGG-MA hydrogels loaded with the VEGF blocker dendrons. It compares the efficacy of this 
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new VEGF blocker dendrons to the linear WHLPFKC sequence by firstly an in vitro three 
dimensional (3D) EC sprouting test and later validated by an in ovo model. At a relatively 
low therapeutic concentrations, FFGen3K(WHLPFKC)16 were able to expand the anti-
angiogenic activity of iGG-MA hydrogel discs by not only preventing the formation of new 
EC sprouting, but also leading to their confined regression in the peri-implantar space. This 
level of control has fundamental importance for the regeneration of those tissues where 
angiogenesis needs to not be completely eliminated.   
2. Materials and Methods 
2.1. VEGF Blocker Synthesis and Characterisation  
Poly-(ɛ-lysine) dendrons (Gen3K) were synthesised with a di-phenylalanine core molecule 
(FF), a L-lysine core consisting of three levels of branching and a tethering with sixteen 
linear VEGF blocker peptide (WHLPFKC)16 exposed at their uppermost branching 
generations as previously reported by Meikle et al. (2011). Briefly, the synthesis of both the 
linear WHLPFKC  and the FFGen3K(WHLPFKC)16 started by coupling to a commercially-
available resin for peptide synthesis an acid-labile Rink amide linker (0.4 mmol, Iris Biotech 
GmbH) later allowing the cleavage of the final product. Both types of peptidic aptamers were 
assembled by repeated coupling reactions, whereby each Fmoc-α-amine-protected amino acid 
unit (0.4 mmol, Novabiochem) was activated by 0.45 M O-Benzotriazole-N,N,N’,N’-
tetramethyluronium-hexafluoro-posphate (HBTU, Novabiochem) and 33 % (v/v) N,N-
diisopropylethylamine (DIPEA, Sigma Aldrich Co. Ltd) and reacted at 60⁰C for 5 minutes. 
At each step, the terminal amino acids were deprotected by removal of their Fmoc group by a 
20 % (v/v) piperidine at 30⁰C for 2 minutes. Following completion of the synthesis, peptides 
were purified using a standard semi-preparative HPLC method (WatersTM 717 plus 
Autosampler) performed on a hydrophobic RP 18 column (150x4.60 mm, Luna 3u C18 100 
Å, Phenomenex) at 25⁰C with a gradient mobile phase composed of a Solvent A (Deionised 
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water/0.1 % Trifluoroacetic Acid) and a Solvent B (Acetonitrile/0.1 % Trifluoroacetic acid). 
The eluate was visualised by UV light lamp at 230 nm (UVP Chromato-vue Cabinet). The 
collected peak fractions were identified by ESI-TOF mass spectrometry (Bruker microTOF).  
 
2.2. Preparation of VEGF Blocker-Functionalised iGG-MA hydrogel discs 
iGG-MA hydrogel discs were prepared according to an established protocol (Silva-Correia et 
al., 2011) where iGG-MA powder was initially dissolved with either WHLPFKC  or 
FFGen3K(WHLPFKC)16 in distilled water at the final concentration of 2 % (w/v). Under 
continuous agitation at 42°C, a stable functionalised gellan gum solution was formed and 
deposited as droplets of 100 µL on the bottom of dry 24-well tissue culture plates (Fisher 
Scientific). The samples were left at 4°C overnight to allow the setting of the hydrogel. Non-
functionalised iGG-MA hydrogel discs were prepared by the same procedure and used as 
control in all the experiments. 
 
2.3. Endothelial Cell Sprouting 3D tests on Non- and Blocker-Functionalised iGG-MA 
hydrogels 
HUVEC suspension (3x104cells/mL) (ATCC) was mixed with MatrigelTM (BD Biosciences) 
in ice-cold conditions in a total volume of 200 µL per well and rapidly pipetted onto the non- 
and VEGF blocker-modified iGG-MA drops ensuring the complete embedding of the 
hydrogels into the 3D matrix. After 30 minutes of incubation, the cells were treated with 1 
mL of fresh endothelial basal medium (F-12K medium, PAA) containing 0.05 mg/mL of 
endothelial cell growth supplement (ECGS, Sigma Aldrich Co. Ltd), 0.1 mg/mL of heparin 
(Fisher Scientific) adjusted to a final concentration of 10% (v/v) of foetal bovine serum (FBS, 
PAA) for 24 and 48 hours at 37°C, under a 5% CO2 and 95% air flow in a relative humidity 
condition. The ability of VEGF blocker dendrons to control capillary like-structure formation 
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was analysed by capturing images at 10x magnification from six different fields for each 
experimental well using a phase contrast microscopy (Nikon Eclipse TE2000-U) fitted with a 
digital camera (Nikon D1X). Whereas, to the purpose of monitoring the blocker release 
between iGG-MA and the surrounding Matrigel matrix, all samples were fixed with 4% (v/v) 
paraformaldehyde (Fisher Scientific) for 10 minutes at room temperature, followed by 
washing in water and staining with haematoxylin and eosin stain (H&E). Specimens were 
then observed under a phase contrast microscopy (Nikon Elipse TE 200U) and images 
captured using a digitised camera at 10 and 20x magnification (Canon LM Scope).  
 
2.4. Quantitative Analysis of Endothelial Cell Sprouting 
Due to the faster rate of diffusion of the linear form from the iGG-MA hydrogel mesh, 
quantitative analyses were performed on FFGen3K (WHLPFKC)16 – laden iGG-MA samples 
versus control ones. 
  
Light microscopy images (8-bit) were analysed using a specific image-processing software, 
Image J/Analyze Skeleton (http://fiji.sc/AnalyzeSkeleton). The programme allowed the 
automated measurement of the mean value of sprouting length, number of free un- and 
associated termination points and junctions within an endothelial capillary-like network. This 
was obtained by skeletonising each EC sprout into a more compact representation while 
preserving the main features of the original image (Figure 1) (Valapala et al., 2011).  
Based on the H&E-stained images (n=6), the number of EC nuclei per capillary-like structure 
was also counted after marking each nucleus as a black dot for easier identification and 
finally reported in an Excel file format.  
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2.5. CAM Model and Tissue Specimen Preparation 
White fertilised chicken eggs (n=5, Pintobar, Portugal) were incubated at 37°C (Laboratory 
Incubator Series 8000, Termaks) for 3 days. Afterwards, albumen of 2.5 mL was extracted 
using a sterile syringe while the CAM of the fertilised egg was separated from the top part of 
the shell. This formed a small visible window (maximum of 15 mm in diameter) that allowed 
the easy evaluation and access to the CAM. The hole was sealed using a transparent tape 
(50x30 mm; BTK) to the purpose of preventing dehydration and any damage of the 
embryonic tissues. The eggs were placed at 3°C and 60% humidity until day 10 of embryonic 
development. At this time point, both non- and aptamer-functionalised iGG-MA discs were 
placed on the top of each CAM membrane. After 4 days of incubation, all CAM implants (n= 
5 for each group) showing contact with host tissues were harvested and immediately fixed 
with 4% paraformaldehyde (Merck) for 10 minutes at -80°C. Samples were then dehydrated 
through a series of increasing ethanol (Fisher Scientific) concentrations for 2 hours and 
embedded in paraffin. The tissue blocks were allowed to cool for 2 hours and then carefully 
sectioned (5 µm) using a rotary microtome (Leica RM2135, Technologic Ltd). To promote 
tissue adhesion, the paraffin sections were mounted onto glass slides (VWR International 
Ltd) coated with 0.1% (w/v) gelatine (Aldrich-Sigma Ltd) and incubated at 60°C in an oven 
overnight. 
 
2.6. Blood Vessel Identification by H&E and Lectin Staining 
Paraffin sections were de-waxed with xylene (National Diagnostic) and ethanol (Fisher 
Scientific) for 10 minutes, followed by washing in water and by staining with hematoxylin 
(Sigma Aldrich Co. Ltd) for 6 minutes at room temperature. After washing under running tap 
water, sections were dehydrated in 90% (v/v) ethanol for 10 seconds, counterstained with 
eosin (Sigma Aldrich Co. Ltd) for 1 minute and dehydrated in a graded series of ethanol 
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rinses. Slides were soaked in 100% (v/v) ethanol and xylene for 3 minutes and then covered 
with a glass coverslip with DPX mounting medium (Fisher Scientific). Stained tissues were 
observed under a phase contrast microscopy (Nikon Elipse TE 200U) equipped with digital 
camera (Canon LM Scope) at 10 and x20 magnification. For lectin staining, tissue samples 
were treated with a solution of Fluorescein isothiocyanate (FITC)-conjugated lectin (Aldrich-
Sigma Ltd) at the final concentration of 100 µg/mL and incubated in a humid chamber at 4°C 
overnight. Afterwards, all the slides (n=6) were carefully rinsed with distilled water and 
imaged using a confocal laser scanning microscopy (Leica UK), whereas signals were 
recorded in the green channel with an excitation 488 nm and emission 522 nm.  
 
2.7. Morphometric Image Analysis  
Morphometric image analysis was performed according to a published method (Gresta et al., 
2014) whereby two hot spots at: i) central, and ii) iGG-MA interface regions of the 
surrounding tissue were identified and documented using an image analysis programme 
(Image J, http://rsb.info.nih.gov/ij/). Those areas were identified by dividing a single mosaic 
into a set of individual images (n=24) at a magnification of x10 and used for counting the 
number of blood vessels previously observed by phase contrast microscopy (Nikon Elipse TE 
200U). The mean values of the vessel count were then divided by the hot spot area (in µm2) 
and considered as microvessel density (MVD) as illustrated in Figure 2. 
 
2.8. Statistical Analysis 
All results from both in vitro and in ovo experiments were tested for statistical difference 
using one-way analysis of variance (ANOVA). A p value ≤ 0.05 was accepted as statistically 
significant for a 95% confidence interval while data were expressed as means ± standard 
deviation (SD).  
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3. Results 
3.1. In vitro Sprouting Inhibition Test at the iGG-MA Material/Tissue Interface 
The results showed that iGG-MA hydrogel discs prevented EC tube infiltration (Figure 3). 
However, when the hydrogels were functionalised with both linear and VEGF blocker 
dendrons their anti-angiogenic capacity to inhibit HUVEC sprouting formation was expanded 
to the surrounding tissue and, in the case of the VEGF blocker dendron, confined to the iGG-
MA/tissue boundary after both 24 and 48 hours incubation (Figure 3, dashed lines). Instead, a 
more extended area of inhibition was observed in the case of hydrogels pre-loaded with linear 
WHLPFKC in which a relatively rapid diffusion of the peptides from the iGG-MA hydrogel 
discs to the surrounding Matrigel led to an inhibition of the sprouting already after 24 hours 
(Figure 3, grey arrows). This trend was more pronounced at 48 hours compared to that of 
FFGen3K(WHLPFKC)16 where inhibition was limited to the iGG-MA/Matrigel interface 
(Figure 3, white arrows). At the same experimental points, the non-modified control material 
interface showed to be colonised by a well-organised and compacted network of capillary-
like structures at 24 and 48 hours after plating (Figure 3, black arrows). 
 
The pattern of controlled angiogenesis in the VEGF blocker–modified iGG-MA hydrogel 
discs was confirmed by the H&E staining of the samples (Figure 4). An uptake of staining by 
the scaffold allowed the clear identification of the material boundary (Figure 4, dashed lines), 
thus showing the degree of contact between its surface and the capillary-like network in both 
the non- and aptamer-functionalised hydrogel discs. Noticeably, extented sprouting covered 
the whole area of inspection and clear contacts with the iGG-MA surface was observed in the 
control (Figure 4, black circle) as opposed to those samples loaded with both linear and 
dendron VEGF blockers (Figure 4, white arrows). In FFGen3K(WHLPFKC)16–modified 
iGG-MA hydrogel discs, the formation of pre-existing tubular structures around the hydrogel 
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surface appeared to regress after 48 hours of incubation (Figure 4, white arrows). Figure 5 
(A) shows a reduction in the average number of branching points 4.71±1.62 µm2 (control 
iGG-MA = 6.93±1.69 µm2) and associated to a higher number of free unassociated points 
3.12±2.68 µm2  (control iGG-MA samples= 0.95±0.74 µm2) (Figure 5 A). Similar results 
were observed in terms of the number of junctions [un-treated iGG-MA samples = 9.13±1.24 
µm2; functionalised iGG-MA samples = 2.77±1.65 µm2] (Figure 5 B) with no significant 
difference in the total average of branch length [un-treated iGG-MA samples = 24.43±2.26 
µm2; functionalised iGG-MA samples = 22.26±4.14 µm2] (Figure 5 C). There was no 
significant difference in the total number of cells between non- [385±86.7 cells/field] and 
dendron-laden iGG-MA hydrogel discs [289±87.8 cells/field] at the tissue/iGG-MA interface, 
respectively (Figure 5 D). 
 
3.2. CAM of iGG-MA and Dendron-laden iGG-MA Hydrogel Discs 
Both non- and aptamer -laden iGG-MA hydrogel discs were well-tolerated by the host tissue 
membrane after implantation as no necrosis or significant host response was detected. Light 
microscopy analysis of the non-treated samples revealed the presence of elongated blood 
vessels that longitudinally converged towards the material at the tissue/iGG-MA interface 
(Figure 6 A, black arrows). These appeared sinusoidal and uniformly dilated (Figure 6 A, 
black circle) when compared to the FFGen3K(WHLPFK)16-laden iGG-MA samples. Indeed, 
this active angiogenesis process was not observed in aptamer-laden iGG-MA samples 
whereby capillaries were irregularly shaped (Figure 6 A, white arrows), smaller and clustered 
after 4 days of implantation (Figure 6 A, white dashed circle on black background).  
Similar anti-angiogenic effects of VEGF blocker dendrons were observed in sections stained 
with lectin as illustrated in Figure 6 B.  A large number of sizable and elongated blood 
vessels, which were oriented parallel along the length of the iGG-MA hydrogel perimeter, 
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were detected only in the control samples (Figure 6 B, black arrows). Such enhanced 
organisation was lost in the presence of FFGen3K(WHLPFKC)16, which promoted growth of 
smaller (Figure 6 B, white dashed circle on black background) and convoluted (Figure 6 B, 
white arrows) capillaries that were either far or randomly distributed at the tissue/iGG-MA 
interface (Figure 6 B, dashed lines) at days 4 implantation.  
 
Figure 7 shows MVD and a decreased number of blood vessels within the 
FFGen3K(WHLPFKC)16-laden iGG-MA samples (16±2.8 vessels/µm2) when compared to 
the control hydrogels (48±3.4 vessels/µm2). However, MVD values showed a similar trend in 
the central areas (untreated iGG-MA samples = 150±1.2 vessels/µm2; 
FFGen3K(WHLPFKC)16-functionalised iGG-MA samples =135± 3.2 vessels/µm2) of the two 
tested samples as illustrated in Figure 7 A. Moreover, the total number of blood vessels was 
found to be similar throughtout the tissue undergoing the implants of both non- and -
functionalised hydrogels (Figure 7 B).  
 
4. Discussion 
A known VEGF blocker sequence has been integrated at the uppermost branching generation 
of dendrons that have specifically been designed to enhance availability of the biospecific 
aptamers and to improve retention in and controlled delivery from hydrogels for tissue 
engineering. The tailor-made design had already shown the clinical potential of this novel 
class of aptamers (Meikle et al., 2011). They were based on the amino acid lysine which 
contains an alkyl amino side-chain capable to allow the branching into a larger 
macromolecule with an overall structure presenting the biospecific sequences at relatively 
high density and in an orderly-spaced manner to the surrounding biological micro-
environment. This type of dendron was assembled using a new microwave-assisted SPPS 
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method that offered speed and high yield of reaction and ultimately an effective control over 
the synthesis of the FF-Gen3K(WHLPFKC)16. Such dendrons have been synthesised to have 
a root of FF capable of preferentially interacting with macromolecules of the tissue 
extracellular matrix (i.e. collagen) and an hyperbranched structure or protein scaffold capable 
to expose an increased density of anti-angiogenic peptide sequence (WHLPFKC) at their 
uppermost branching generation (Meikle et al., 2011). WHLPFKC has been recently isolated 
by phage display technique (Erdag et al., 2007) and demonstrated to be capable of 
establishing a bond with human VEGF165 at molar ratio of 1:1 even in presence of both Type 
I and II collagen [our unpublished data]. Forming a stable complex with the angiogenic 
growth factor, this linear peptide essentially antagonised the autocrine VEGF effects on 
HUVECs in vitro. However, when grafted to a dendron scaffold, its bioavailability and 
biological actvity was successfully maximised providing evidence for the control of 
proliferation and regression of capillary-like structures in HUVECs. Moreover, the relatively 
hydrophobic nature of these VEGF blocker dendrons enhances their potential to penetrate 
collagenous matrices and to revert angiogenesis in absence of cytotoxicity (Meikle et al., 
2011). On the basis of this evidence, the tailored-design of the material in the present study 
enabled a control over the release of VEGF blocker sequences by: (i) reducing the problem of 
burst release from the gel associated with the relatively smaller linear aptamer through an 
increase of the molecular weight and through the enhancement of physical interactions 
between the di-phenylalanine groups at the root of the dendrons and the methacrylate 
hydrophobic residues of the iGG-MA and (ii) increasing the density and space distribution of 
the aptamer through the exposure of sixteen units per dendrimer. Although specific 
rheological studies were not investigated in this paper, it was observed that the hydrogel 
formed a more compact structure when dendrons were encapsulated in it supporting the 
occurrence of hydrophobic interaction within the gel mesh. This more compact structure of 
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the hydrogel could also have played a role in limiting the release of the VEGF blocker 
dendrons. The overall outcome is the significant clinical advantage of having the anti-
angiogenic effect circumscribed to the immediate surrounding of the implant. Indeed, the 
contrast phase microscopy analysis demonstrated that, when compared to the non-modified 
iGG-MA, the FF-Gen3K(WHLPFKC)16 -laden biomaterial induced a regression of the 
capillary-like structures typical of the Matrigel endothelial sprouting assay only at the 
hydrogel boundary. Contrariwise, a more pronounced area of inhibition could be observed in 
the case of the biomaterial where the linear peptide had been entrapped. At cellular level, this 
effect can be attributed to cell apoptosis in absence of sufficient levels of VEGF as the 
microscopy highlighted morphological changes with HUVECs showing blebbing and round-
shaped morphology. Altogether these data  indicate the efficiency of the VEGF blocker 
dendrons in inhibiting the endothelial sprouting from existing capillary-like structures which 
is known to be strictly dependent on VEGF-related activity (Ahmad et al., 2011) and suggest 
a potential advantage in clinical applications such as the regeneration of the nucleous 
pulposus of the intervertebral disc where the formation of new avascular tissue needs to 
coexhist with the vascularised annulus fibrosus. 
 
The data obtained by the in ovo model supported the findings of the in vitro study and added 
more information related to the effect of the VEGF blocker dendron release on a highly 
vascularised tissue such as the chorioallontoic membrane surrounding the chick embryo. Both 
control and aptamer-functionalised iGG-MA hydrogel discs prevented blood vessel 
infiltration mainly because of the relatively tight structure of the gel mesh. However, those 
samples that had been modified by the encapsulation of the VEGF blocker dendron allows 
the formation only of thinner and rounded vessels that failed to develop especially at the 
tissue/iGG-MA interface in a manner similar to the regression by cell blebbing and rounding 
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observed in vitro and in line with other studies demonstrating the key role of VEGF 
concentration gradients in angiogenesis (Shamloo et al., 2012). The qualitatively-assessed 
reduction in MVD at the boundary of aptamer-functionalised iGG-MA samples, but not in the 
central areas, is corroborated by previous work showing similar findings in cases where 
vessel morphology and size changed with interferences in the local VEGF concentration 
levels (Ozawa et al., 2004). These authors found that low VEGF expression induced 
destabilised retinal capillaries gradually regressing rather than progressing into angiogenesis. 
The disruption of the interaction of the VEGF molecule with its receptor on the endothelial 
cell membrane appeared to be one of the determinants in this critical event (Nakatsu et al., 
2003). Although in our results the average number of capillaries was not significantly 
different between analysed samples, recent genetic studies in mice have reported that 
targeting blood vessel function and stabilisation, rather than their numbers, may provide an 
alternative approach to prevent angiogenesis in tissue regeneration (Loges et al., 2010; 
Alvarez et al., 2009).  
 
5. Conclusions 
In this study, FF-Gen3K(WHLPFKC)16 showed to represent a potentially useful 
biofunctionalisation strategy to enhance the clinical performance of cartilage tissue 
engineering based on iGG-MA hydrogel discs. The fine control of angiogenesis around the 
gel boundary is likely to impede the invasion of blood vessels from the surrounding 
vascularised tissue independently from its tight mesh. As the biomaterial is absorbed and new 
tissue is formed, it is likely that angiogenesis will not overcome avascular cartilage as its 
penetration will no longer be stopped by the tight mesh, but rather by the sustained but 
circubscribed release of the aptamer; a property that cannot be achieved by the use of the 
small molecular weight, linear VEGF blocker WHLPFKC. 
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Figure Captions 
 
 
Figure 1. Steps of image preparation (Left panel) and HUVEC tube identification (Right 
panel) using a skeletonised method by Image J (Valapala et al., 2011). (A) An original image 
was initially, (B) skeletonised by highlighting EC tubes in white running over a black 
background, (C) tagged for pointing out the “positive” tube structures (purple), and (D) 
assessed with regards branch points and length (orange/white) free un-associated points 
(purple) and actual junctions (blue) between EC tubes. Scale bar is 50 µm.     
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Figure 2. Example of blood vessel analysis and quantification. (A) A mosaic image was 
morphometrically analysed by dividing the (B) individual sections into two distinct hot spots 
located at the (C) centre and (D) iGG-MA interface of the tested tissues. Scale bar is 300 and 
150 µm. 
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Figure 3. Effect of VEGF blockers integrated in iGG-MA hydrogel discs on the formation of 
HUVEC tubes at 24 and 48 hours. Dashed lines indicate the approximate position of the iGG-
MA hydrogel discs; grey and whitearrows point out the capacity of both WHLPFKC and 
FFGen3K(WHLPFKC)16 to induce an EC sprouting inhibition at the iGG-MA boundary when 
compared to the control (black arrows). Scale bar is 100 and 50 µm. 
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Figure 4. H&E staining of both untreated and functionalised iGG-MA samples. (A) centre; 
(B) iGG-MA interface. Circle evidences contacts between iGG-MA boundary and the tube 
network while white arrows indicate an area of capillary-like structures in phase of regression 
at the biomaterial interface (dashed lines). Scale bar is 50 µm. 
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Figure 5. HUVEC tube analysis and quantification of both tested samples. (A) Average of 
number of branch and free un-associated points; (B) total of junctions; (C) branch length and 
(D) number of cells associated with HUVEC tubes at the biomaterial interface. (n=6). 
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Figure 6. Functionalised iGG-MA hydrogel discs showed ability to affect blood vessel 
maintenance. (A) H&E, and (B) lectin staining. Blood vessels of regular shape and size were 
found to longitudinally run towards the biomaterial boundary only in the control samples 
(black arrows). Such activity was completely lost in presence of FFGen3K (WHLPFKC)16 
whereby capillaries appeared tortuous (white arrows), clustered (white dashed circle on black 
background) and either far or irregularly distributed at the biomaterial interface (dashed 
lines). Scale bar is 50 and 250 µm. 
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Figure 7. Quantification of both MVD and number of blood vessels within the non- and 
treated iGG-MA samples. Changes in (A) MVD values associated with higher, and (B) 
number of capillaries were found throughout of the control compared to the iGG-MA with 
FFGen3K(WHLPFKC)16. (n=24).  
 
 
 
 
